Cargando…
Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
INTRODUCTION: Admissions for acute bacterial skin and skin structure infections (ABSSSI) are often prolonged because of intravenous (IV) antibiotics. Use of a long-acting IV antibiotic may reduce length of stay (LOS) on a hospitalist service. The ENHANCE ABSSSI trial sought to determine the impact o...
Autores principales: | McCarthy, Matthew W., Keyloun, Katelyn R., Gillard, Patrick, Choi, Justin J., Pickell, Nicholas, Copp, Ronald, Walsh, Thomas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054506/ https://www.ncbi.nlm.nih.gov/pubmed/31713130 http://dx.doi.org/10.1007/s40121-019-00275-4 |
Ejemplares similares
-
456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial
por: McCarthy, Matthew W, et al.
Publicado: (2019) -
Pharmacist-Directed Use of Dalbavancin in Acute Bacterial Skin and Skin Structure Infections to Reduce Hospital Length of Stay
por: Jones, Bruce, et al.
Publicado: (2017) -
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017) -
Pathway with single‐dose long‐acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections
por: Talan, David A., et al.
Publicado: (2021) -
1365. Clinical and Financial Implication of Dalbavancin Utilization on Length of Stay Avoidance in Acute Bacterial Skin and Skin Structure Infection
por: Kim, Sonia S, et al.
Publicado: (2021)